Gilead takes legal action against counterfeit HIV drug networkUS pharma giant Gilead Sciences has accused a network of unauthorised suppliers and distributors of selling more than Share XGilead takes legal action against counterfeit HIV drug networkhttps://pharmaphorum.com/news/gilead-takes-legal-action-against-counterfeit-hiv-drug-network/
FDA okays ViiV’s Apretude as first injectable for HIV PrEPGlaxoSmithKline’ majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir Share XFDA okays ViiV’s Apretude as first injectable for HIV PrEPhttps://pharmaphorum.com/news/fda-okays-viivs-apretude-as-first-injectable-for-hiv-prep/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
Gilead files Truvada follow-up Descovy for PrEPGilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending Share XGilead files Truvada follow-up Descovy for PrEPhttps://pharmaphorum.com/news/gilead-files-truvada-follow-up-descovy-for-prep/
